Banca de QUALIFICAÇÃO: GABRIELA MASTRANGELO GONÇALVES

Uma banca de QUALIFICAÇÃO de DOUTORADO foi cadastrada pelo programa.
DISCENTE : GABRIELA MASTRANGELO GONÇALVES
DATA : 04/07/2019
HORA: 13:00
LOCAL: Sala 01 - PQ
TÍTULO:

The Role of the Brain Derived Neurotrophic Factor (BDNF) in Depression

PALAVRAS-CHAVES:

Depression, neuroplasticity, BDNF, antidepressants

PÁGINAS: 20
GRANDE ÁREA: Ciências Biológicas
ÁREA: Farmacologia
SUBÁREA: Neuropsicofarmacologia
RESUMO:

According to data published in 2017 by the World Health Organization (WHO), the total number of people living with depression in the world is 322 million. The consequences of this disturbance are enormous. Depression is considered the main contributor to the deaths caused by suicide, which reaches 800,000 per year. Characterized by disturbances in cognition, emotional regulation, memory and neurovegetative symptoms, depression can cause a severe disability that adversely affects the quality of life of affected individuals. The mechanisms related to the pathophysiology of depression are complex and have not yet been fully elucidated, but several studies point to some theories such as hypothalamic-pituitary-adrenal (HHA) axis abnormalities, monoaminergic neurotransmitter impairment, inflammatory processes, vascular, genetic and epigenetic alterations , in addition to the reduction of neurogenesis and neuroplasticity. The process of neuroplasticity is controlled by neurotrophins, proteins found in the central nervous system that perform their functions promoting growth and differentiation of new neurons and synapses. BDNF (brain-derived neurotrophic factor) is considered to be the main neurotrophin in the brain, it has expression mainly in the hippocampus, neocortex, amygdala and cerebellum. BDNF is directly related to learning and memory mechanisms. Furthermore, there is growing evidence suggesting that the BDNF signaling pathway may be involved in the pathophysiology of depression, as well as in the therapeutic action of antidepressant drugs. Studies have shown that BDNF levels are decreased in depressed patients. Even more important, perhaps, is the fact that reduced amounts of BDNF can be restored to normal levels with chronic antidepressant treatment. Another relevant fact is the ability of BDNF to cross the blood-brain barrier, and its serum and plasma levels have a high correlation with BDNF found in cerebrospinal fluid, and can then be used as a biomarker in depressive disorder.

MEMBROS DA BANCA:
Interno - 1519567 - FABIO FAGUNDES DA ROCHA
Interno - 387295 - LUIS CARLOS REIS
Externo ao Programa - 2151322 - JAQUELINE ROCHA BORGES DOS SANTOS